Use of Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDs

Use of Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDs

Identifying anti-spike antibodies that exhibit strong neutralizing activity against current dominant circulating variants, and antibodies that are escaped by these variants, has important implications in the development of therapeutic and diagnostic solutions and in improving understanding of the hu...

Full description

Bibliographic Details
Main Authors: Enqing Tan, Erica Frew, Jeff Cooper, John Humphrey, Matthew Holden, Amanda Restell Mand, Jun Li, Shaya Anderson, Ming Bi, Julia Hatler, Anthony Person, Frank Mortari, Kevin Gould, Shelly Barry
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Diagnostics
Subjects:
COVID-19
SARS-CoV-2 variant
lateral flow immunoassay
spike protein
receptor binding domain (RBD)
neutralizing antibody
Online Access:https://www.mdpi.com/2075-4418/11/7/1190

Internet

https://www.mdpi.com/2075-4418/11/7/1190

Similar Items